Heron Therapeutics amends CEO and executive severance, equity acceleration provisions

HERON THERAPEUTICS, INC. /DE/

CEO Craig Collard's amended agreement: severance of 1x base salary + bonus (non-CIC) or 2x (CIC), plus equity acceleration.
For performance-based equity granted after April 3, 2026, vesting accelerates at greater of actual performance or target upon qualifying termination.
Similar amendments for CFO Duarte, CDO Forbes, COO Hensley: 12 months pay & equity (non-CIC) or 24 months & full acceleration (CIC).
Agreements add 24-month non-competition and non-solicitation covenants; governing law changed to North Carolina.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.